CagriSema

FDA-approved GLP-1 medications and their generic active ingredients.

Definition

Novo Nordisk's investigational fixed-dose combination of cagrilintide (long-acting amylin analog) plus semaglutide (GLP-1 agonist). REDEFINE 1 reported 20.4% mean weight loss at 68 weeks (22.7% adherent estimand) versus 14.9% with semaglutide alone. Novo has filed an NDA. The result missed Novo's 25% guidance benchmark but still beat semaglutide monotherapy.

CagriSema REDEFINE trial results →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Drugs and brands

Wegovy
Ozempic
Rybelsus
Saxenda
Zepbound
Mounjaro
Foundayo
Semaglutide
Tirzepatide
Orforglipron
Retatrutide
Cagrilintide
Survodutide
MariTide (Maridebart Cafraglutide)
Ecnoglutide

Looking for more depth?

CagriSema REDEFINE trial results
Browse the full GLP-1 glossary (51 terms across 8 categories)
Research articles — primary-source deep dives
Tools and calculators
Compare GLP-1 telehealth providers